RecruitingPhase 2NCT07213973
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa
Sponsor
Incyte Corporation
Enrollment
40 participants
Start Date
Feb 2, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
Eligibility
Min Age: 12 YearsMax Age: 17 Years
Inclusion Criteria8
- Aged ≥ 12 to \< 18 years at the time of informed consent/assent signing.
- Body weight ≥ 30 kg at both screening and baseline visits.
- Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit.
- Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits.
- HS lesions corresponding to refined Hurley Stage IB, IC, IIB, IIC, or III at both the screening and baseline visits.
- Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for treatment of their HS).
- Agreement to use contraception.
- Willing and able to comply with the study protocol and procedures.
Exclusion Criteria4
- Presence of \> 20 draining tunnels (fistulas) at either the screening or baseline visit.
- Women who are pregnant (or who are considering pregnancy) or breastfeeding.
- Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
- Laboratory values outside of the protocol-defined ranges.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPovorcitinib
Oral; Tablet
Locations(27)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07213973
Related Trials
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
NCT0728764433 locations
A Study With CIT-013 in HS Patients
NCT0699323324 locations
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498330 locations
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
NCT0699361056 locations
The Safety and Efficacy of Roflumilast Foam in HS
NCT072632301 location